Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TEKAMLO vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of aliskiren (direct renin inhibitor) and amlodipine (dihydropyridine calcium channel blocker). Aliskiren inhibits renin, reducing angiotensin I and II formation; amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Treatment of hypertension (FDA-approved) as replacement therapy in patients adequately controlled on individual components,Off-label: Not established
Hypertension
One tablet (40 mg telmisartan/5 mg amlodipine) orally once daily; maximum dose: 80 mg telmisartan/10 mg amlodipine per day.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Amlodipine terminal half-life: 30-50 hours (mean 35 hours), allowing once-daily dosing; steady-state achieved after 7-8 days. Valsartan terminal half-life: ~6 hours, but pharmacodynamic effect persists due to tight AT1 receptor binding.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Aliskiren: minimal metabolism via CYP3A4; amlodipine: extensively metabolized by CYP3A4
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
TEKAMLO (amlodipine/valsartan) excretion: amlodipine is extensively metabolized in the liver with 60% of metabolites excreted renally and 20-25% via feces; unchanged drug in urine <10%. Valsartan is primarily excreted unchanged in feces (70-80%) via biliary elimination, and 13% in urine as unchanged drug.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Amlodipine: ~97.5% bound to plasma proteins (albumin). Valsartan: 94-97% bound to serum proteins (mainly albumin).
~90%, primarily to albumin
Amlodipine Vd: ~21 L/kg, indicating extensive extravascular distribution. Valsartan Vd: ~5-10 L/kg, indicating moderate distribution into tissues.
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Amlodipine: oral bioavailability 64-90% (mean ~64%). Valsartan: oral bioavailability ~23% (range 10-35%). Both are administered orally only.
Oral: 50–60% (extensive first-pass metabolism)
No adjustment for GFR ≥30 m L/min. Contraindicated if GFR <30 m L/min due to telmisartan component. Amlodipine not dialyzable.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Use lowest available strength, titrate slowly; avoid if severe impairment.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Safety and efficacy not established in patients <18 years.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at lowest available strength (40/5 mg); titrate slowly due to increased risk of hypotension and renal impairment.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Risk of hypotension/syncope in volume-depleted patients,Avoid use in pregnancy (potential fetal harm),Monitor renal function and electrolytes, especially in patients with renal artery stenosis,Peripheral edema (more common in women, dose-dependent)
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Concomitant use with aliskiren in patients with diabetes or renal impairment (e GFR <60 m L/min) due to increased risk of renal impairment, hypotension, and hyperkalemia,Pregnancy,History of angioedema with aliskiren
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid grapefruit and grapefruit juice; they inhibit CYP3A4 metabolism of amlodipine, increasing risk of toxicity. Limit high-potassium foods (e.g., bananas, oranges, leafy greens, salt substitutes) due to aliskiren's potential to raise serum potassium. Maintain adequate hydration but avoid excessive sodium intake. No significant interaction with alcohol but advised to limit consumption.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Fetal toxicities (oligohydramnios, renal dysfunction, skull ossification delay) with angiotensin II receptor blocker (ARB) class. Second/third trimester: Oligohydramnios, fetal renal failure, hypotension, hyperkalemia, skull hypoplasia; risk is highest in second and third trimesters.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
No human data; amlodipine excreted in breast milk (M/P ratio ~1.0), telmisartan unknown. Avoid use while breastfeeding due to potential for neonatal hypotension and renal effects.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
No dose adjustment recommended due to lack of pharmacokinetic studies in pregnancy; however, drug is contraindicated in pregnancy, especially second and third trimesters, and alternative antihypertensives should be used.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Tekamlo is a fixed-dose combination of aliskiren and amlodipine. Monitor renal function and electrolytes due to aliskiren's renin inhibition; avoid in severe renal impairment (e GFR <30 m L/min). Amlodipine may cause peripheral edema, especially at higher doses. Gradual titration reduces edema risk. Do not use aliskiren with ACE inhibitors or ARBs in patients with diabetes or renal impairment (e GFR <60 m L/min).
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take this medication exactly as prescribed, usually once daily.,Do not use with other blood pressure medications unless directed by your doctor.,Avoid grapefruit and grapefruit juice as they can increase amlodipine levels and side effects.,Report signs of edema (swelling in ankles/feet), dizziness, or fainting.,Do not take if you are pregnant or planning to become pregnant; stop immediately if pregnant.,Do not use salt substitutes containing potassium without consulting your doctor.,Stay hydrated, but avoid excessive intake of potassium-rich foods (bananas, oranges, spinach).,Do not stop abruptly without medical advice; monitor blood pressure regularly.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TEKAMLO vs ALDORIL 15, answered by our medical review team.
TEKAMLO is a Antihypertensive combination that works by Combination of aliskiren (direct renin inhibitor) and amlodipine (dihydropyridine calcium channel blocker). Aliskiren inhibits renin, reducing angiotensin I and II formation; amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle, causing vasodilation.. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TEKAMLO and ALDORIL 15 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TEKAMLO is: One tablet (40 mg telmisartan/5 mg amlodipine) orally once daily; maximum dose: 80 mg telmisartan/10 mg amlodipine per day.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TEKAMLO and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TEKAMLO is classified as Category C. First trimester: Fetal toxicities (oligohydramnios, renal dysfunction, skull ossification delay) with angiotensin II receptor blocker (ARB) class. Second/third trimester: Oligohydr. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.